Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

The Stakes of Antibiotic Stewardship

JUL 22, 2020 | GRANT M. GALLAGHER
Segment Description: Dr. Pol Vandenbroucke, Chief Medical Officer for Pfizer’s hospital business unit, talks about what makes antibiotic stewardship so important to clinicians and researchers.


Related Coverage:

The AMR ACTION FUND

More than 20 biopharmaceutical companies are collaborating on an initiative to develop 2-4 antibiotics in 10 years in order to counteract antimicrobial resistance.

The AMR Action Fund, an initiative of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), an international body representing the R&D pharmaceutical industry, was announced at simultaneous virtual launch events in Berlin and Washington, DC.

“With the AMR Action Fund, the pharmaceutical industry is investing nearly $1 billion to sustain an antibiotic pipeline that is on the verge of collapse, a potentially devastating situation that could affect millions of people around the world,” Chairman and CEO of Eli Lilly and Company and President of IFPMA David Ricks said. 


Read full story.

To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.